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Available online 01 August 2017Osteoarthritis (OA), affecting joints and bone, causes physical gait disability with huge socio-economic burden;
treatment remains palliative. Roles for antioxidants in protecting against such chronic disorders have been exam-
ined previously. Sulforaphane is a naturally occurring antioxidant. Herein, we explore whether SFX-01®, a stable
synthetic form of sulforaphane, modifies gait, bone architecture and slows/reverses articular cartilage destruction
in a spontaneous OA model in STR/Ort mice. Sixteen mice (n= 8/group) were orally treated for 3 months with
either 100mg/kg SFX-01® or vehicle. Gait was recorded, tibiaeweremicroCT scanned and analysed. OA lesion se-
verity was graded histologically. The effect of SFX-01® on bone turnovermarkers in vivowas complemented by in
vitro bone formation and resorption assays. Analysis revealed development of OA-related gait asymmetry in vehi-
cle-treated STR/Ort mice, which did not emerge in SFX-01®-treated mice. We found significant improvements in
trabecular and cortical bone. Despite thesemarked improvements,we found that histologically-gradedOA severity
in articular cartilagewas unmodified in treatedmice. These changes are also reflected in anabolic and anti-catabol-
ic actions of SFX-01® treatment as reflected by alteration in serum markers as well as changes in primary osteo-
blast and osteoclast-like cells in vitro. We report that SFX-01® improves bone microarchitecture in vivo,
produces corresponding changes in bone cell behaviour in vitro and leads to greater symmetry in gait, without
marked effects on cartilage lesion severity in STR/Ort osteoarthritic mice. Our findings support both osteotrophic
roles and novel beneficial gait effects for SFX-01® in this model of spontaneous OA.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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STR/Ort1. Introduction
Osteoarthritis (OA) has major joint and bone hallmarks, and is the
most common cause of gait impairment and physical disability [1]. It is
clear that OA has major genetic and mechanical determinants, yet its
complex aetiology means that its features remain poorly understood.
OA affects all facets of joint integrity, with thinning of the articular carti-
lage accompanied by subchondral bone thickening, alongwith formation
of bony osteophytic projections [2]. The role of bone, especially the
subchondral plate, in the initiation and progression of OA has been the
subject ofmany studies [3–6]. Clinical studies have reported an elevation
in indices of bone formation and resorption [7], suggesting that boneences, Royal Veterinary College,
. This is an open access article underremodelling is enhanced in OA patients. Despite such improvement in
our understanding of OA, effective treatment options remain limited.
The significant socio-economic burden this creates, requires develop-
ment of newdisease-modifying drugswhich effectively targetOA chang-
es in cartilage and bone.
To identify OA-modifying drug targets, various mouse OA models
have been used [8,9], including:models inwhichOA arises spontaneous-
ly, such as in STR/Ort mice [9,10]. Male STR/Ort mice develop a natural
OA, aged ∼20 weeks that engages processes resembling those seen in
human OA, with a loss of articular cartilage proteoglycan, progressive ar-
ticular cartilage degeneration, osteophytogenesis, and subchondral bone
thickening [10–12]. Methods formonitoring OA severity in STR/Ort mice
include cartilage lesion grading after termination [13] as well as non-in-
vasive monitoring of gait [14], which has been linked with OA severity
and knee pain in humans [15,16]. It has also been reported that STR/
Ort mice have high bone mass, however, how this is related to OA pro-
gression remains to be clarified [17,18].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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includingOA, has been studied extensively. One indirect antioxidant, sul-
foraphane (SFN), is a naturally-occurring potent modulator of phase II
xenobiotic-metabolizing enzymes. SFN is found at high concentrations
in precursor form, as glucoraphanin, in cruciferous vegetables, particu-
larly broccoli (Brassica oleracea italica) [19] and is released by hydrolytic
myrosinase activity. SFN (1-isothiocyanato-4-methylsulphinylbutane)
activates the transcription factor NF-E2–related factor 2 (Nrf2), which
binds to an antioxidant response element in cognate genes. SFN is rapidly
absorbed by humans and previous studies have reported anti-inflamma-
tory effects [20]. It has recently emerged that SFN also protects retinal
pigment epithelial cells, pancreatic islet β-cells, kidney, skeletal muscle,
vascular smooth muscle cells, cardiomyocytes and neurons against oxi-
dative stress.
SFN also modulates expression of matrix metalloproteinases in
chondrocytes [21] and has been reported to regulate osteoclastogenesis
by inhibiting receptor activator of nuclear factor-κB ligand (RANKL)
[22]. An exciting recent study extended these effects of SFN to the pro-
tection of articular cartilage destruction [23]. These authors found that
administration of a SFN-rich diet significantly reduced cartilage destruc-
tion 12 weeks after induction of OA by surgical destabilisation of the
medial meniscus (DMM) [23]. It was acknowledged, however, that sur-
gically induced OA is not necessarily an ideal model in which to assess
the protective role of SFN, and that SFN is inherently unstable, rendering
it a nonviable pharmaceutical agent.
Indeed, SFN is known to degrade in response to heat, is sensitive to
light, oxygen and is affected by pH changes [24,25]. Recently, SFN was
stabilised by formation of a synthetic sulforaphane-alpha-cyclodextrin
inclusion complex, leading to the generation of a stable compound,
named Sulforadex (SFX-01®), which has provided the opportunity to
utilize the full potential of SFN. In the present study, we have explored
whether SFX-01® slows and/or reverses the destruction of cartilage in
the STR/Ort model of spontaneous OA. To achieve this, we use both
non-invasive monitoring of gait modifications, as well as extensive
post-mortem analysis of joint and bone disease hallmarks to examine
howOA in thesemice is influenced by in vivo SFX-01® treatment. Final-
ly, the effect of SFX-01® on mouse osteoblast and osteoclast function
was assessed using established in vitro protocols.
2. Materials and methods
2.1. Animals
Male STR/Ortmicewere housed in a facility at 21±2 °Cwith 12-hour
light/dark cycles at the Royal Veterinary College (RVC) in polycarbonate
or polypropylene cages with wood chip and paper bedding. The mice
were housed up to 4 per cage; weaners up to 8 weeks of age were fed
a standard rodent breeding diet and thereafter a standard rodent main-
tenance diet (Special Diet Services, SouthWitham, UK). All of the proce-
dures conducted in the facility were in accordance with the Animals Act
(Scientific Procedures) 1986 and local RVC ethical guidelines.
2.2. SFX-01® treatment
At 26 weeks of age, sixteen male STR/Ort mice (n= 8/group) were
assigned randomly to vehicle and SFX-01® groups and were treated
orally for 3 months with daily administration of either 100 mg/kg SFX-
01® (a stable form of SFN, PharmAgra Labs, CN, USA) or vehicle, 0.5% so-
dium carboxymethyl cellulose (Sigma, Poole, Dorset, UK) in H2O.
2.3. Gait analysis
Gait was recorded using a treadmill-basedDigiGait™ Imaging system
(Mouse Specifics Inc., Boston, MA) [26] before sacrifice. Briefly, vehicle
and SFX-01® treated mice (8 per group) ran on a transparent flat tread-
mill at 17 cm/s, while a video camera captured ventral images. Animalsran for a maximum of 30 s, with segments of 5 s (which corresponded
to N10 consecutive strides) used for analysis. No habituation procedures
were used for these studies at any time. DigiGait image analysis software
automatically defines each paw area, generates waveforms to describe
advance/retreat of each limb in consecutive strides, and identifies pe-
riods of time when each paw is in treadmill contact as stance phase,
and intervening periods as swing phase. Postural and kinematic gait
measurementswere also calculated according tomanufacturers' instruc-
tions. Symmetry indices, symmetry ratios, compensation and balance
between the contralateral fore and the hind limbs were computed [27].
The minimum and maximum of these asymmetry measures were re-
corded as primary and secondary descriptors.
From those gait descriptors symmetry and balance indexeswere cal-
culated as:
Symmetry index ðSI;100  jR−Ljð Þ= 0:5  R þ Lð Þ½ 
Symmetry ratios:
¾ Between Hind and Fore Limbs in the same (right and left) side
¾ Between both fore limbs and between both hind limbs
Compensation or balance between the contralateral fore and the hind
limbs:
¾ Between the right-hind and left fore-limbs: dgr = |RR-LF|
¾ Between the left-hind and right fore-limbs: dgl = |LR-RF|
where RR, LR, RF, LF referred to right-rear, left-rear, right-fore and
left-fore limbs. The minimum and the maximum of those values, as
well as the minimum of their ratio were computed. In total, there were
262 different gait descriptors. These measures of asymmetry allow for
the unpredictable targeting of OA to specific hind-limb knee joints in
this strain of STR/Ort mouse to be monitored. Greater symmetry indi-
cates more ‘normal’ gait pattern (with the proviso that alternatively
both limbs may be equally affected).
Mouse treadmill task noncompliance (i.e. refusal to undertake or
complete the treadmill running task, whichwould be observed as inabil-
ity or unwillingness of a mouse to take N2 consecutive strides) was also
recorded [14].
2.4. High-resolution micro-computed tomography (micro-CT)
2.4.1. Scanning
Micro-CT scanning and analysis were performed as described previ-
ously [28]. Briefly, tibiae from vehicle and SFX-01® treated groups (n=
8/group) were fixed in neutral buffered formalin (NBF) and subse-
quently stored in 70% EtOH until scanning using the Skyscan 1172
(Skyscan, Kontich, Belgium), with x-ray tube operated at 50 kV and
200 μA, 1600 ms exposure time with a 0.5 mm aluminium filter and
voxel size of 10 μm (~2 h scan time per sample). The slices were recon-
structed using NRecon 1.6.9.4 (Skyscan, Kontich, Belgium). 2D/3D anal-
yses were performed using CTAn 1.15.4.0+ version software (Skyscan,
Kontich, Belgium). Finally, CTvox 3.1.0 r1167 version (Skyscan, Kontich,
Belgium) was used for 3D visualisation and production of colour-coded
images of trabecular thickness.
2.4.2. Morphometrical analysis
2.4.2.1. Metaphyseal/epiphyseal trabecular and subchondral cortical analy-
sis. Appearance of the trabecular ‘bridge’ connecting the two primary
spongiosa bone ‘islands’ was set as reference point for analysis of the
metaphyseal trabecular bone adjacent to the epiphyseal growth plate.
5% of the total bone length from this point (toward the diaphysis) was
utilised for trabecular analysis of the proximal tibia [28,29]. Epiphyseal
trabecular bone was analysed as described previously [12].
2.4.2.2.Whole bone cortical analysis.Whole bone analysis was performed
on datasets derived from whole CT scans using BoneJ [30](version
1.13.14) a plugin for ImageJ. Following segmentation and removal of
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each bone to separate higher density bone from soft tissues and air.
This threshold was used in “Slice Geometry”within BoneJ plugin to cal-
culate cross sectional area (CSA), secondmoment of area aroundminor
axis (Imin), second moment of area around major axis (Imax) and mean
thickness determined by local thickness in 2D (Mean Thick).
2.5. Histology and grading of articular cartilage (AC) lesions
Dissected knees were fixed in neutral buffered formalin, decalcified
(Immunocal, Quartett, Berlin), wax-embedded and 6 μm coronal sec-
tions cut. Multiple slides (∼10), each containing five, 6 μm sections sam-
pled at 120 μm intervals spanning entire joint of vehicle and SFX-01®
treated STR/Ort joints (n = 8) were stained with Toluidine blue (0.1%
in 0.1 M acetate buffer, pH 5.6) and AC lesion severity scored by the
methods of Chambers et al. [31], consistent with an internationally-
recognised system [13]. Briefly, grade 0: normal; grade 1: rough surface
or superficial zone lesions; grade 2: lesion down to the intermediate
zone; grade 3: lesions down to tidemark or loss of AC; grades 4 and 5:
AC loss across between 20% and 50% or 50–80% of condylar surface;
grade 6: loss with subchondral bone exposure. Grading in each joint
compartment (lateral/medial, tibia/femur) allowed for a maximum
(most severe) grade to be assigned in each section, and used to produce
an overall ‘average’maximum grade in each group ofmice, for the entire
joint and for each compartment. In addition, amean scorewas produced
for each joint and for each compartment and these similarly used to pro-
duce an overall ‘average’ mean grade in each group of mice.
2.6. Assessment of osteophyte maturity and of non-AC joint tissues
Osteophyte maturity was scored as described [32]. Briefly, multiple
Toluidine blue-stained sections (as AC grading), spanning each joint
were graded. Grade 0: no osteophyte; grade 1: predominantly cartilagi-
nous; grade 2: mixed cartilage and bone; grade 3: predominantly bone
withmarrow spaces. Maximum scores on internal and external condylar
margins were recorded.
2.7. Hemeoxygenase-1 (HO-1) enzyme-linked immunosorbent assay
(ELISA)
Mouse ImmunoSet HO-1 ELISA (Enzo Life Sciences, Exeter, UK) was
performed according to manufacturer's instructions. Briefly 96-well
high-binding polystyrene microtiter plates were coated with the HO-1
capture antibody, overnight at room temperature (RT) andwere blocked
with blocking solution for 1 h the following day. Standards and samples
were added and incubated for 1 h at RT. Following 4 washes with wash
buffer, sampleswere incubatedwith detection antibody for 1 h at RT. Fol-
lowing another set of washes, the plate was incubated for 30 min with
Streptavidin, Horseradish Peroxidase (SA-HRP) conjugate. HRP activity
was revealed using 3, 3′, 5, 5′-tetramethylbenzidine (TMB) for 30 min,
stop solution was applied and excitation and emission were measured
at 450 nm. Amount of HO-1 protein in ng/mL was calculated using the
standard curve. HO-1 protein levels were normalized to total released
protein.
2.8. Bone biomarker analyses
Serum samples were collected at the time of sacrifice and stored at
−80 °C. Serum levels of C-terminal crosslinking telopeptide of type-I col-
lagen (CTX-I), a marker of bone resorption, and total procollagen type 1
N-terminal propeptide (P1NP)were quantified by Serum Rat-Laps ELISA
assay (Immunodiagnostic Systems Ltd., Boldon, UK), following the
manufacturer's instructions.2.9. Mouse osteoblast cultures
Primary cells were derived from the calvarial bones of 2–4 day old
mice. Osteoblasts were obtained using methods similar to those previ-
ously described [33]. Briefly, calvariae were digested using 0.25% trypsin
for 10 min, 0.2% collagenase in Hank's buffered salt solution (HBSS) for
30 min, and finally 0.2% collagenase in HBSS for 60 min, all at 37 °C.
The first two digests were discarded and cells from the final digest
were resuspended in α-modified essential medium supplemented
with 10% foetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin,
0.25 μg/ml amphotericin B (mixture abbreviated to ‘α-MEM’). Osteo-
blasts were cultured for 4 days in 75 cm2 flasks in a 5% CO2 atmosphere
at 37 °C until confluent. Upon confluence, cells were plated into 6-well
trays in α-MEM further supplemented with 2 mM β-glycerophosphate
and 50 μg/ml ascorbate. Osteoblasts were treated with 1 nM–10 μM
SFX-01® or PBS (vehicle) for the duration of the culture. Experiments
were terminated by fixing the cells in 2.5% glutaraldehyde for 5 min.
Cell culture plates were imaged at 800 dpi using a flat-bed scanner
(Epson Perfection 4990 Photo) and the total area of bone nodules formed
was quantified by image analysis, as described previously [33].
2.10. Mouse osteoclast cultures
The long bones were dissected from 6 week-old mice, cut across the
epiphyses and the marrow was flushed out with PBS. The resulting sus-
pension was centrifuged at 1500 rpm and resuspended in MEM supple-
mented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin,
100 nM prostaglandin E2 (PGE2) and 50 ng/ml macrophage colony stim-
ulating factor (M-CSF). The cell suspension was cultured for 24 h in a
75 cm2 flask in 5% CO2/95% atmospheric air to allow attachment of stro-
mal cells and other rapidly adherent cells. The non-adherent cell suspen-
sion was removed, centrifuged and resuspended in MEM supplemented
with 100 nM PGE2, 200 ng/ml M-CSF and 3 ng/ml RANKL (R&D Systems
Europe Ltd., Abingdon, UK). Cells were plated onto 5mm diameter ivory
discs (106 cells/disc) in 96-multiwells. After 24 h, discs containing adher-
ent osteoclast precursors were transferred to 6well trays (4 discs/well in
4mlmedium) for a further 6 days at 37 °C in 5% CO2/95% atmospheric air.
Culture medium was acidified to pH ~7.0 by the addition 10 meq/l H+
(as HCL) on day 7 to activate osteoclasts to resorb dentine. SFX-01®
(1 nM–10 μM) was added for the duration of the culture.
Osteoclasts were fixed in 2% glutaraldehyde and stained to demon-
strate tartrate-resistant acid phosphatase (TRAP). Osteoclasts were de-
fined as TRAP-positive cells with 2 or more nuclei and/or clear
evidence of resorption pit formation. Osteoclast number and the area
resorbed on each discwere assessed ‘blind’ by transmitted lightmicros-
copy and reflective light microscopy and dot-counting morphometry,
respectively.
2.11. Statistical analysis
For treadmill data, Fisher's exact test was used to assess drop-out be-
tween groups. In addition, a principal component analysis was per-
formed to extract the important information from the gait multivariate
data and to express this information as a set of new uncorrelated vari-
ables (principal components, PC). For this purpose, the function PCA()
from theR package “FactoMineR”was used (“R”, version 3.1.3; R Founda-
tion for Statistical Computing, Vienna, Austria; http://www.r-project.
org). A Student t-test (function t-test() from the R package “stats”) was
performed to determine whether the mean of most important PC dif-
fered between both groups of animals.
A Shapiro–Wilk normality test (GraphPad Prism 6; GraphPad Soft-
ware, Inc., SanDiego, CA)was performed on all the datasets; all exhibited
P-values ≤ 0.05. Two samples Student's t-test was applied to determine
the effect of SFX-01® treatment on metaphyseal and epiphyseal
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0.05 was considered significant.
For cortical bone, graphs were developed using the R programming
language “R”, version 3.1.3. Normality and homogeneity of variance of
data were checked using the Shapiro-Wilk and the Bartlett's test in the
R 3.1.3 respectively. Two-sample t-test was used to compare means be-
tween vehicle and SFX-01® treated groups. Data are expressed as
mean ± SEM and values were considered statistically significant when
p ≤ 0.05. For in vitro experiments, data were analysed using a one-way
ANOVA, followed by a Bonferroni post hoc test. For all in vitro work, re-
sults are expressed as means ± SEM between 6 and 8 biological repli-
cates and are representative of experiments performed at least three
times using cells isolated from different animals.
3. Results
3.1. SFX-01® treatment corrects OA-associated gait asymmetry
Gait wasmonitored using a treadmill-based video system at 17 cm/s
in vehicle and treated groups. The asymmetry index for each variable
fromeach individual vehicle and SFX-01® treatedmousewas calculated
and these data used in unbiased principal component analysis aimed to
examine the effect of SFX-01® treatment and to identify any other pat-
terns. Despite multiple opportunities, 4/8 vehicle-treated and 2/8 SFX-
01® treated mice failed to ever complete the treadmill task (‘drop-
out’). Thus, 4 control and 6 treated mice successfully completed the
treadmill task, and there was no significant difference in drop-out rate
between the two groups (p= 0.61).
The importance of PC's is illustrated in Fig. 1A and indicates that 64.6%
of the variation contained in the data are retained by the first three prin-
cipal components and 81.1% in the first 5 PC's. Among these 8 PC's, only
the second PC reached levels that were significantly different between
vehicle and SFX-01® treated mice (Fig. 1B; p ≤ 0.05). We found that ve-
hicle and not SFX-01® treated groups of animals clearly differ for PC2.
The most important gait descriptors associated with PC2 clearly segre-
gate the SFX-01® treated and vehicle mice and are shown in Fig. 1C. In
addition, distribution of vehicle and SFX-01® treated mice are shown
in Fig. 1D. Together these data indicate a significantly greater symmetry
and synchronisation of movement and gait that is more rhythmic and
less turbulent in SFX-01® compared with vehicle treated spontaneously
osteoarthritic (control) STR/Ort mice.
3.2. SFX-01® treatment alters trabecular bone in both epiphyseal and
metaphyseal compartments but has no effect on the tibial subchondral
plate
To investigate whether SFX-01® treatment modifies bone mass and
architecture we examined bone in both the tibial epiphyseal and
metaphyseal trabecular compartments, as well as bone of the tibial
subchondral plate in vehicle and treated mice using high-resolution
μCT. Analysis of both lateral andmedial tibial subchondral bone plate re-
gions revealed that subchondral plate thicknesswas not significantly al-
tered in either lateral ormedial tibial plateau compartments in response
to SFX-01® treatment (Fig. 2A). Furthermore, we found that there was
no significant effect of SFX-01® treatment on subchondral plate tissue
volume (TV), bone volume (BV) and percent bone volume (BV/TV) in
either compartment (Fig. 2B–C).
Epiphyseal trabecular TV was, however, significantly greater in STR/
Ort mice after SFX-01® treatment (Fig. 2E; p ≤ 0.05) and, despite small
non-significantmodification in epiphyseal trabecular BV, BV/TVwas sig-
nificantly reduced by SFX-01® treatment in the epiphysis (Fig. 2E; p ≤
0.05). However, trabecular thickness was not significantly altered in re-
sponse to SFX-01® treatment (Fig. 2D). In addition to epiphyseal bone,
we analysed metaphyseal bone in 5% of the total tibial length starting
from the end of primary spongiosa. Our data reveal that SFX-01® treat-
ment of STR/Ortmice also significantly increasedmetaphyseal trabecularTV (Fig. 2G; p ≤ 0.05) and, in this compartment, that this was accompa-
nied by increases in BV (Fig. 2G; p ≤ 0.05) and BV/TV (Fig. 2G; p ≤
0.05), with significantly higher trabecular number and mean moment
of inertia (MMI) compared with the vehicle-treated group (Table 1). In
agreement with the effect of SFX-01® treatment on epiphyseal trabecu-
lar bone, we found that trabecular thickness (Fig. 2F), separation and de-
gree of anisotropy (Table 1) were also not significantly altered in this
bone compartment in response to SFX-01® treatment. Together these
data reveal that SFX-01® treatment of STR/Ort mice results in an expan-
sion of the epiphyseal total volume, without any statistically significant
increases in bone volume and hence a reduction in BV/TV in the epiphy-
seal trabecular bone compartment whilst, in contrast, treatment pro-
duces an enhancement in the trabecular total volume, bone volume
and consequently bone mass in the metaphyseal compartment.
3.3. SFX-01® treatment improves cortical bone mass and predicted indices
of tibia strength
To determine whether osteotrophic effects of SFX-01® in STR/Ort
mice extended to the bone cortices we undertookwhole-bone tibia cor-
tical analysis. We found no significant effect of SFX-01® treatment on
body weight or tibial length (Fig. 3A) in STR/Ort mice. Nonetheless, cor-
tical cross sectional area (CSA) was greater at many locations along the
tibia length in SFX-01®-treated STR/Ort mice and reached statistically
significant levels in the distal-most tibial region, from ~60% of length
(Fig. 3C). Mean cortical thickness was only altered in small regions at
the proximal and distal ends (Fig. 2B–C).
To provide an estimate of how these changes in cortical bone area
modify tibial resistance to bending forces, we also calculated the second
moment of area aroundminor (Imin) andmajor axes (Imax) aswell as pre-
dicted resistance to torsion (J) and tibial shape asmeasured by ellipticity.
These data showed that both Imin and Imax in tibiae of SFX-01® treated
STR/Ort mice deviate from patterns observed in vehicle treated mice;
Imin was significantly greater along almost the entire tibial length
(apart from a region ~50–60% of length) and Imin was significantly ele-
vated toward the distal tibia of STR/Ortmice treatedwith SFX-01®. Tibial
shape as indicated by ellipticity was unaffected, yet predicted resistance
to torsion (J) was significantly elevated in the SFX-01® treated mice at
many locations mainly in proximal and distal tibia of STR/Ort mice.
These data indicate that SFX-01® treatment in the STR/Ort model of
spontaneous OA leads to significant enhancement in cortical bone area,
Imin and Imin that consequently lead to enhanced predicted index of tor-
sional, bending strength.
3.4. SFX-01® does notmodify indices of natural OA in joints of STR/Ortmice
To establish the effect of SFX-01® treatment on natural OA develop-
ment, as assessed by scoring of AC lesion severity, we investigated differ-
ent components of tibiofemoral complex in STR/Ort mice. OA develops
predominantly inmedial tibia plateau of STR/Ortmice [10].We therefore
scored both OA mean and maximum grades in both medial and lateral
joint compartments and found that neither mean nor maximum OA
scores were modified by SFX-01® treatment in STR/Ort mice.
We also examined the presence of osteophytes using toluidine blue
stained sections scored according to a grading system described previ-
ously [32] (Fig. 4G–H). Our data show that osteophytes developed sim-
ilarly in each of the compartments of the knee joint in both SFX-01® and
vehicle treated STR/Ort mice (Fig. 4H) and that neither the presence or
severity of osteophytes was modified by SFX-01® treatment (Fig. 4G).
Similarly, we found by microCT that SFX-01® treatment did not alter
the overall thickness (Fig. 4I) nor the TV, BV and BV/TV of the menisci
in STR/Ort mouse joints (Fig. 4J). Taken together, these data show that
SFX-01® treatment did not modify these indices of OA severity, namely
AC lesions, osteophytes or mineralised meniscal mass and architecture
in STR/Ort mice.
Fig. 1. SFX-01® treatment corrects OA-associated gait asymmetry (A) Scree graph displaying percentage of variance explained by each of the first 8 principal components. (B) Average
values of each of the first 8 PC's in SFX-01® (grey) and vehicle treated (black) mice and the corresponding p-values (beneath graph) of the differences between these groups. (C) The
top 10 gait descriptors that associated with principal component 2 (dotted red line corresponds to the expected value if the contribution where uniform). (D) Scatterplot showing the
significant segregation of individual vehicle (closed circles) and SFX-01® (closed triangles) treated mice on the basis of the first 2 PCs. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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To explore themechanismunderpinning the SFX-01®-inducedmod-
ifications in bone mass and architecture in STR/Ort mice, we next exam-
ined both hepatic markers of classic downstream antioxidant, anti-
inflammatory targets of native SFN and serummarkers of bone remodel-
ling in vivo. To assess whether SFX-01® targets the classic downstream
antioxidant, anti-inflammatory targets of native SFN, we first measured
levels of hemeoxygenase-1 (HO-1; a downstream target of the nuclear
factor, erythroid-derived 2-like 2 (Nrf2) promoter [34]. Our data showed
that hepatic HO-1 protein levels were significantly upregulated by SFX-
01® treatment (Fig. 5A; p ≤ 0.05), suggesting its in vivo targeting of
mechanisms resembling SFN.
To assess the effect of SFX-01® on new bone formation in vivo, we
measured serum levels of procollagen type I NH2-terminal propeptide
(PINP). As shown in Fig. 5B, PINP levels were significantly elevated in re-
sponse to SFX-01® treatment in STR/Ort mice (p ≤ 0.05). In cultured pri-
mary osteoblasts, 10–100 nM SFX-01® produced modest changes in
both area and number of mineralised nodules, however, neither reached
levels of statistical significance (Fig. 5C and D). Treatment with 10 μMSFX-01® almost completely abolished mineralised bone nodule forma-
tion (Fig. 4C–E; p ≤ 0.05).
We also found that serum levels of C-telopeptide of type I collagen
(CTX-I), a bone resorption marker was significantly decreased in SFX-
01® treated STR/Ort mice compared with vehicle-treated controls
(Fig. 5F; p ≤ 0.05). In primary osteoclast cultures SFX-01® treatment
(100 nM, 1 μM, 5 μM, 10 μM) dose-dependently reduced osteoclast
number and resorption by up to 100% (Fig. 5G–H; p ≤ 0.05). Together,
these data show that SFX-01® likely activates classic downstreamtarget
protein to exert its actions in STR/Ort mice and that these responses
evoke enhanced rates of remodelling with enhanced bone formation
in vivo and decreased indices of bone resorption both in vivo and in vitro.
4. Discussion
There is a lack of effective, disease-modifying pharmacological drugs
available to treat OA and existing treatments that target symptoms are
often inadequate. Non-pharmacological treatments, including physio-
therapy and exercise, are ineffective for OA management and joint re-
placement remains often the only treatment offered to patients
Fig. 2. Proximal epiphyseal and metaphyseal tibial bone phenotype of vehicle (black) and SFX-01® treated (grey) mice after 11 weeks of treatment starting at 26 weeks of age. (A)
Representative colour-coded thickness images of lateral and medial tibial subchondral plate of vehicle and SFX-01® treated mice. (B and C) Total volume (TV), bone volume (BV) and
bone volume fraction (BV/TV) of medial (B) and lateral (C) proximal tibial subchondral plate. (D) Representative colour-coded thickness images of epiphyseal trabecular bone of
vehicle and SFX-01® treated mouse tibia. (E) TV, BV and BV/TV of tibial epiphyseal trabecular bone. (F) Representative colour-coded thickness images of metaphyseal trabecular bone
of vehicle and SFX-01® treated mice. (g) Ex vivo analyses to determine TV, BV and BV/TV of metaphyseal trabecular bone. Bar graphs represent means ±SEM. Group sizes were n= 8
for vehicle and treated mice. Statistical comparisons: * denotes p ≤ 0.05.
313B. Javaheri et al. / Bone 103 (2017) 308–317reaching end-stage OA [35,36]. Previous studies have used different
food-derived antioxidant pharmacological agents for the prevention or
reversal of chronic degenerative disorders including OA. Among these
agents, SFN has shown promising protection through cell cycle arrest,
apoptotic, anti-angiogenic and anti-inflammatory actions [19,37]. SFN
is, however, unstable.
Herein, we explored whether a stabilised form of SFN, namely SFX-
01®modifies gait andbone architecture, and slows/reverses the destruc-
tion of AC during spontaneous progression of OA in STR/Ort mice. STR/
Ort mice have been used previously in interventional studies aimed at
identifying targets that prevent and protect against AC lesions in OA
joints. These have shown the importance of MMPs in AC degradation
in STR/ort mice by administration of Ro 32-3555, an orally activeTable 1
Meanvalue ofmorphometric parameters representing trabecularmass and architecture of
vehicle and SFX-01® treatedmice. Group sizes were n=8 for vehicle and treated groups.
Two-sample t-test was used to comparemeans between vehicle and treated. Normality or
the homogeneity of variance assumption were not violated (p ≥ 0.05). Data are mean
± SEM.
Morphometric index Vehicle Treated P value
n= 8 n= 8 Vehicle vs treated
Trabecular parameters
Trabecular number (Tb.N) 2.75 ± 0.26 3.10 ± 0.47 b0.05
Mean moment of inertia (MMI) 0.200 ± 0.02 0.275 ± 0.04 b0.001
Trabecular separation (Tb.Sp) 0.295 ± 0.02 0.275 ± 0.05 NS
Degree of anisotropy (DA) 1.52 ± 0.10 1.37 ± 0.16 NScollagenase selective inhibitor, which protected against OA development
[38]. In addition, intra-articular injections of CRB0017 (anti-ADAMTS5
antibody) dose-dependently slowed OA progression in STR/Ort mice
across a slightly older 5–8 month age range than we used [39]. Our
data reveal that treadmill task non-compliance and the development of
asymmetric gait (most obviously demonstrated in uneven distribution
in hind limb paw area in left/right limbs), which is normally linked to
OA [14] in vehicle-treated STR/Ort mice, failed to emerge in SFX-01®-
treatedmice; fore-limb asymmetry followed similar patterns. Our previ-
ous studies comparing gait in STR/Ort and sex-/age-matched non-osteo-
arthritic CBA mice (closest commercially available parental strain)
showed that unlike STR/Ort, CBA mice show full treadmill task compli-
ance and that paw area and gait asymmetries were the best predictor
of age-related OA onset and severity.
In contrast, we found that histologically-graded OA in articular carti-
lagewas unmodified by SFX-01® treatment and hence unlikely linked to
any correction of OA-related gait asymmetry. The OA scoring systemwe
use is closely aligned to an internationally-recognised system devised by
Osteoarthritis Research Society International (OARSI) for grading of OA
joints in animalmodels. Itwas devised to bemore sensitive acrossmilder
OA grades and applicablewithmore consistently by less experienced ob-
servers than the original system proposed by Mankin [40–43]. Applica-
tion of this scoring system to different OA murine models was highly
reproducible [13] and we have used it to grade OA in mice of this age
group previously under both similar and other conditions [14,44,45].
Its application to early OA stages in have also been found to correlate
with mRNA levels of molecular markers of OA development in STR/Ort
Fig. 3. Cortical bone phenotype of vehicle (black) and SFX-01® (grey) treated mice. (A) Whole body weight and tibial length of vehicle and SFX-01® treated mice after 11 weeks of
treatment. (B) Representative 3D Micro-CT colour-coded images of tibial cortical bone thickness. (C) Bone cross sectional area (CSA) and mean cortical thickness, (D) minimum and
maximum second moments of area (Imin and Imax respectively) and (D) ellipticity and J (resistance to torsion) of vehicle and SFX-01® treated STR/Ort mice. Whole bone analyses of
cortical bone between 10 and 90% of total tibial length, excluding proximal and distal metaphyseal bone. A two-sample t-test was used to compare means between vehicle KO and
SFX-01® treated STR/Ort mice. Line graphs represent means ± SEM. Group sizes were n = 8 for vehicle and treated mice. Graphical heat map summarises statistical differences at
specific matched locations along the tibial length, representative of overall effect of SFX-01® treatment. Red p ≤ 0.000–0.001, yellow p ≤ 0.001–0.01, green p ≤ 0.01–0.05 and blue p ≥
0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
314 B. Javaheri et al. / Bone 103 (2017) 308–317mouse cartilage [46]. Thus, our studies which failed to identify any ben-
eficial effect of SFX-01® in articular cartilagemake it highly unlikely that
thesemolecular signatureswill have been affected by the very long-term
SFX-01® treatment.
We have previously reported that gait changes in STR/Ort mice are
not necessarily accompanied by any measurable local inflammatory
joint pain, such as that induced by intraarticular injection of Freund's
complete adjuvant (CFA). This indicates that hind limb paw area mea-
surement may be a useful, non-invasive monitoring tool that likely re-
flects structural, rather than local inflammatory pain-related, changes in
the joint. Previous studies have reported the presence of low thresholds
formechanical stimuli, pain and hyperplasia in patientswith OA suggest-
ing a non-nociceptive pain element. These observations have provided
evidence to support the notion that neuropathic pain mechanisms con-
tribute to thepain experience of theOApopulation [47–49]. Interestingly,
recent studies have suggested that SFN is an effective treatment for other
forms of neuropathic pain [50]. Our data indicate that SFX-01® treatment
corrects the OA-associated asymmetries in gait that occur in untreated
STR/Ort mice, without modifying articular joint scores, suggesting that
SFX-01® targets a component of OA-linked neuropathic pain that is hith-
erto unidentified in the spontaneous OA that occurs in these mice.
Our detailed analyses of different components of tibiofemoral com-
plex as well as entire tibial cortical bone reveal that SFX-01® treatmentof STR/Ort mice produces an enhancement in trabecular bone mass in
themetaphysis, an expansion of the volume but not significant alteration
in bonemass in the epiphysis without anymodifications in the thickness
of the subchondral plate. We consider these differences to be dominated
by the more marked volumetric increases in the epiphysis vs. the
metaphysis. Previous studies have shown that subchondral bone partic-
ularly is important in the pathogenesis of OA [3–6,51] and that this
should be targeted by OA-modifying drugs [52]. Several studies have re-
ported, using different bone modifying agents in animal models and in
cells in vitro including oestrogen [53], bisphosphonate [54], intermittent
parathyroid hormone [55] and strontium ranelate [56] are capable of
modifying subchondral bone remodelling and OA progression. It is also
interesting to note that some clinical trials using bone antiresorptive
and anabolic drugs have suggested that OA-linked pain is improved in
response to these selective bone modifying agents [57]. Our findings
strengthen the possibility that these bone-targeting therapies may
have some merit, since we find that SFX-01® treatment both modifies
bone architecture in the STR/Ortmice and likely reducesOApain and im-
proves gait, without seemingly influencing the AC lesions severity in the
joints of these mice. It is important, nonetheless, that long-term pain re-
lief without directly targeting AC lesion development, may itself predis-
pose joint to alterations in their mechanical loading environment and
thus hasten AC deterioration [58]. Osteophyte formation is also an
Fig. 4. SFX-01® treatment doesnotmodify different compartments of tibiofemoral complex. (A–C) (lower-power) and (B–D) (higher-power), toluidine blue stained sections of joints from
vehicle (A–B) and SFX-01® (C–D) treated STR/Ortmice showing locations of naturally occurring lesions in the articular cartilage of themedial femur compartment of the tibiofemoral joint.
Both vehicle and treated groups exhibited localized lesions. (E) and (F), mean andmaximum±SEM lesion severity scores in each compartment of vehicle joints (circle) and treated joints
(square). Osteophytes develop in both SFX-01® and vehicle treated STR/Ort mice; toluidine blue stained sections were scored to provide (G) mean number of osteophytes. (H) MicroCT
was used to produce representative 3D images of osteophytes (green) in vehicle and SFX-01® treated mice. (I) Representative 3DMicro-CT colour-coded images of meniscal phenotype
and (J) ex vivo analyses to determine TV, BV and BV/TV.Group sizeswere n=8 for vehicle and treatedmice. (For interpretation of the references to colour in thisfigure legend, the reader is
referred to the web version of this article.)
315B. Javaheri et al. / Bone 103 (2017) 308–317important characteristic of OA in humans and inmice [59].We, however,
found no effect of SFX-01® treatment on osteophytes and meniscal
mineralised tissue mass and architecture.
Our data also show that treatmentwith SFX-01® leads to a significant
enhancement in cortical bone mass in STR/Ort mice that improves pre-
dicted indices of torsional, bending strength. These significant region-
specific effects of SFX-01® on cortical bone mass and architecture are
possibly due to differences in region specific transcription factor expres-
sion as described previously [60]. We also assume, due to structural dif-
ferences, that load-induced strain distribution and bone remodelling be
different at different anatomical locations. The likelihood that these ef-
fects are achieved by direct actions on bone cells is supported by our
data showing both anabolic and anti-catabolic actions of SFX-01® treat-
ment in vivo, evidenced by alteration in serummarkers, aswell as chang-
es in isolated primary osteoblast and osteoclast-like cell behaviour in
response to exogenous SFX-01® in vitro. Indeed, our results with SFX-
01® are in close agreement with previous studies in which SFN has
been reported to elicit both anabolic and anti-resorptive properties
[22]. Although our in vitro osteoblast assays show a beneficial trend of
SFX-01 treatment, they did not reach statistical significance and hence
do not match perfectly with elevated serum PNIP levels. In our study,STR/Ortmicewere treatedwith daily SFX-01® for 3monthswhereas pri-
mary osteoblastswere only exposed to SFX-01® for days and thus longer
exposure to SFX-01® in vivomight underlie these differences. It is also
possible that SFX-01® affects bone formation indirectly and additional
studies are needed.
It is important to emphasize that the animals used in this study were
26 weeks of age and according to a wealth of historical data, already os-
teoarthritic. It is therefore possible that earlier treatment of STR/Ortmice
with SFX-01® prior to OA initiation (pre-18 weeks of age) might exert
additional protective effects on OA-related cartilage degradation and
other joint markers of OA severity. This is highly likely since previous
studies have reported that SFN can inhibit the activation of a variety of
effector and initiator caspases, critically involved in both intrinsic and ex-
trinsic pathways of chondrocyte apoptosis and cartilage damage in ar-
thritic diseases [61].
In conclusion, we report that SFX-01® improves bone
microarchitecture in vivo, produces corresponding changes in bone cell
behaviour in vitro to enhance indices of bone mechanical strength and
produces greater symmetry in gait, without marked effects on cartilage
lesion severity in STR/Ort osteoarthritic mice. Our findings support
both osteotrophic roles and novel beneficial gait effects for SFX-01®
Fig. 5. SFX-01® treatment activates downstream target (HO-1: hemeoxygenase-1) and controls bone remodelling in vivo and in vitro. (A)HO-1protein level in livermeasured by ELISA. (B) In
vivo blood serum protein level of procollagen type 1 N-terminal propeptide (P1NP: bone formation marker). (C–D) SFX-01® inhibited bone nodule formation at the highest dose only; no
effectswere seen at lower concentrations. (E) Representativewholewell scansof osteoblast cell layers treatedwith different concentration of SFX-01®. (F) In vivoblood serumprotein level of
serum collagen type 1 cross-linked C-telopeptide (CTX-1: bone resorptionmarker). (G) SFX-01®dose-dependently inhibits osteoclast formation and resorptive activity compared to vehicle.
(H) Representative transmitted and reflective light images of osteoclasts treated with 1–10 μM SFX-01®. Graphs represent means ± SEM. Statistical comparisons: * denotes p ≤ 0.05.
316 B. Javaheri et al. / Bone 103 (2017) 308–317that appear to be independent of articular cartilage lesion development
in this model of spontaneous OA.
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